EcoDrugPlus

Cysteinyl Leukotriene Receptor 2-Like

Ensembl ID : ENSXMAG00000002335
Gene Symbol: LOC106700152
2 Cross references
237 Possible Orthologues:

Cytidine Deaminase

Ensembl ID : ENSXMAG00000029412
Gene Symbol: CDA
3 Cross references
200 Possible Orthologues:

Cytochrome P450 26a1

Ensembl ID : ENSXMAG00000014144
Gene Symbol: LOC102237203
3 Cross references
194 Possible Orthologues:

Cytochrome P450 3a30

Ensembl ID : ENSXMAG00000027420
Gene Symbol: LOC102219031
3 Cross references
535 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSXMAG00000009951
Gene Symbol: LOC102237589
3 Cross references
474 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSXMAG00000026665
Gene Symbol: LOC111606488
2 Cross references
528 Possible Orthologues:

Cytochrome P450 3a56-Like

Ensembl ID : ENSXMAG00000017125
Gene Symbol: LOC102222638
2 Cross references
529 Possible Orthologues:

Cytochrome P450 3a56-Like

Ensembl ID : ENSXMAG00000025140
Gene Symbol: LOC111608645
3 Cross references
538 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSXMAG00000006782
Gene Symbol: CYP19A1
4 Cross references
244 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSXMAG00000009310
Gene Symbol: LOC102238126
3 Cross references
188 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSXMAG00000018317
Gene Symbol: LOC106699769
3 Cross references
214 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSXMAG00000028909
Gene Symbol: LOC102238293
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).